Dr. Reddy’s receives approval from the US Food and Drug Administration (USFDA) for its rituximab biosimilar. The approval comes after the USFDA conducts a Pre-License Inspection (PLI) at the company’s biologics manufacturing facility in Bachupally, Hyderabad. Multiple reports describe the development as an FDA nod that follows the inspection process related to the manufacturing site. The information provided across sources focuses on the approval and the fact that it is linked to the USFDA’s inspection of Dr. Reddy’s facility. The reports do not add details on product specifications, expected launch timelines, or market availability. Overall, the coverage centers on the regulatory milestone and the inspection step that precedes approval. The biosimilar is tied to rituximab, a monoclonal antibody used in certain cancer and immune-related conditions, though the shared articles do not specify the approved indications. The sources present the USFDA approval as the key event.